AlirezaFaridarMD

Neurology • Houston, TX

Assistant Professor of Neurology, Houston Methodist Hospital

Join to view full profile

Dr. Faridar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Faridar's full profile

Already have an account?

Office
6560 Fannin St
Ste 802
Houston, TX 77030
Phone+1 713-441-1150

Fax+1 713-793-7012

Education & Training

Methodist Hospital (Houston)Fellowship, Dementia Translational Fellowship, 2017 - 2018
Methodist Hospital (Houston)Residency, Neurology, 2013 - 2017
University of California San Francisco School of MedicinePost-Doctoral Fellowship, 2011 - 2013
Tehran University of Medical Sciences School of MedicineClass of 2008

Certifications & Licensure

TX State Medical License 2017 - 2026
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

BrightFocus Alzheimer Disease Research Fellowship Award 2019
American Neurology Association (ANA) travel award 2013

Clinical Trials

Phase II Clinical Trial of Interleukin-2 in AD Start of enrollment: 2022 Jan 01
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Systemic and Central Inflammation in AD Start of enrollment: 2023 Mar 17
Recruiting
Phase 2
Roles: Contact
IL-2 Plus Abatacept in FTD Start of enrollment: 2024 May 06
Recruiting
Phase 1
Roles: Contact, Principal Investigator

Publications & Presentations

PubMed

2 citations
Brain inflammation co-localizes highly with tau in mild cognitive impairment due to early-onset Alzheimer's disease.
Johanna Appleton, Quentin Finn, Paolo Zanotti-Fregonara, Meixiang Yu, Alireza Faridar
Brain. 2025-01-07
1 citations
A phase 1 proof-of-concept study evaluating safety, tolerability, and biological marker responses with combination therapy of CTLA4-Ig and interleukin-2 in amyotrophic...
Jason R Thonhoff, David R Beers, Weihua Zhao, Alireza Faridar, Aaron Thome
Frontiers in Neurology. 2024-01-01
7 citations
A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer's disease.
Alireza Faridar, Abdulmunaim M Eid, Aaron D Thome, Weihua Zhao, David R Beers
Translational Neurodegeneration. 2023-11-16

Press Mentions

Coya Therapeutics Reports Data from Alzheimer’s Disease Therapy TrialApril 3rd, 2023
Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s DiseaseJune 10th, 2023
Coya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceMarch 1st, 2024
Join now to see all